查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1463782

全球流感診斷市場：市場規模和份額分析（按產品、測試類型和最終用戶）、行業需求預測（截至 2030 年）

Influenza Diagnostics Market Size and Share Analysis by Product, Test Type, End User - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 240 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概況

預計全球流感診斷產業規模將在 2023 年達到 9.469 億美元，並在 2030 年快速成長至 16.031 億美元，預測期內複合年增長率為 7.9%。

由於流感加劇的慢性疾病增加、人口老化以及政府加強追蹤疾病傳播的力度，預計對流感分析解決方案的需求將激增。 技術複雜的感染診斷工具的成長也是該行業的主要驅動力。

關鍵見解

2023年，檢測試劑盒和試劑品類佔60%的市佔率。

這是因為這些疾病現在更常見，人們對早期診斷的關注顯著增加。

2023年，傳統品類以40%的份額引領業界。

此類別的快速診斷流感測試由於其易於使用且快速得出結果而產生了最高的收入。

由於廣泛的政府監管、頂尖公司的存在以及技術的進步，2023 年北美將佔據 65% 的銷售份額。

歐盟 (EU) 人口老化，到 2021 年，超過五分之一的人口年齡在 65 歲或以上，預計將佔人口的相當大比例。

本報告分析了全球流感診斷市場，包括市場的基本結構和最新情況、主要促進和抑制因素以及全球、按地區和主要國家的市場規模前景（以貨幣形式計算） ，（2017-2030） ，按產品、檢驗類型和最終用戶劃分的詳細趨勢、當前市場競爭狀況以及主要公司概況。

目錄

第1章研究範圍

第2章研究方法

第 3 章執行摘要

第 4 章市場指標

第5章產業展望

  • 市場動態
    • 趨勢
    • 促進因素
    • 抑制因素/挑戰
    • 促進/抑制因子影響分析
  • 新型冠狀病毒感染 (COVID-19) 的影響
  • 波特五力分析

第6章世界市場

  • 摘要
  • 市場收入：依產品分類（2017-2030 年）
  • 市場收入：依測試類型劃分（2017-2030 年）
    • 按類型劃分的傳統診斷測試市場收入（2017-2030 年）
    • 分子診斷測試市場收入：按類型劃分（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：按地區劃分（2017-2030 年）

第7章北美市場

  • 摘要
  • 市場收入：依產品分類（2017-2030 年）
  • 市場收入：依測試類型劃分（2017-2030 年）
    • 按類型劃分的傳統診斷測試市場收入（2017-2030 年）
    • 分子診斷測試市場收入：按類型劃分（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）
  • 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第11章中東及非洲市場

第12章美國市場

  • 摘要
  • 市場收入：依產品分類（2017-2030 年）
  • 市場收入：依測試類型劃分（2017-2030 年）
    • 按類型劃分的傳統診斷測試市場收入（2017-2030 年）
    • 分子診斷測試市場收入：按類型劃分（2017-2030 年）
  • 市場收入：以最終用戶劃分（2017-2030 年）

第13章加拿大市場

第14章德國市場

第15章法國市場

第16章英國市場

第17章義大利市場

第18章西班牙市場

第19章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

  • 市場參與者及其提供的產品/服務的列表
  • 主要公司的競爭基準
  • 各大公司的產品基準
  • 近期策略發展狀況

第30章公司簡介

  • 3M Company
  • Abbott Laboratories Inc.
  • Becton, Dickinson and Company
  • Meridian Bioscience Inc.
  • QuidelOrtho Corporation
  • F. Hoffmann-La Roche Ltd.
  • SA Scientific Ltd.
  • Sekisui Diagnostics LLC
  • Thermo Fisher Scientific Inc.
  • Hologic Inc.

第31章 附錄

簡介目錄
Product Code: 12822

Market Overview

The worldwide influenza diagnostics industry generated USD 946.9 million in 2023, which is projected to surge to USD 1,603.1 million by 2030, experiencing a 7.9% CAGR during the projection period.

The requirement for influenza analysis solutions is estimated to surge as a outcome of the growing occurrence of chronic illnesses, several of which are deteriorated by the flu; rising aged populace, and growing government initiatives to track the spread of this illness. The growth of technically complex diagnostic tools for contamination is another major propeller for the industry.

An outbreak of flu can also be a global issue. As a result, huge amounts of R&D initiatives are launched for detection and drug improvement. In the majority of cases, the main research focus is the production of tests that can give fast and precise results on flu viruses in the quickest amount of time.

In 2019, the Centres for Collaborative Research on Influenza Vaccine Innovations (CIVICS) program, which is administered by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), was established to finance a variety of research initiatives pertaining to influenza epidemiology. Generously by NIAID (NIMB), the budgeted amount was USD 51 million emerged as the result of the first year of CIVIC's (Center for Integration of Veterans into the Civic Community) launch.

Key Insights

In 2023, the Test kits and reagent category held a leading market share of 60%.

This is due to the fact that these ailments are currently more common and with a notable rising attention towards early diagnosis.

However, points like ease of access without the necessity of writing a prescription (readily available on the market through pharmacies, retail stores, and online channels), ease of use, quick effect towards weight loss results, and affordable costs result in the growth of this category.

Together with the practical over-the-kit tests, the flu spread can be stopped because the isolated testing can be done without any contact with a suspected carrier.

Point-of-care testing allows people to economize by sending for professionals who are called in to conduct the tests. They also enjoy the tests being easy to conduct by themselves.

In 2023, the traditional category led the industry with a share of 40%.

The category is projected to experience a higher CAGR over the projection period.

Rapid influenza diagnostic tests within this category generated the highest revenue because of their simple use and fast results.

Augmented need for patient handling and surveillance testing for contagions in clinical settings.

Numerous RIDTs are accepted for use at houses and offices, with sanction from CLIA for usage in point-of-care services.

In 2023, the North American region held 65% of the revenue share, because of wide government surveillance, the existence of top companies, and technical improvements.

Well-recognized healthcare infrastructure and helpful reimbursement guidelines propel industry development.

European Union is projected to have a substantial share because of its aging populace, with more than one-fifth being 65 years or more in 2021.

Surging the possibility of flu in elders has led to WHO's recommendation of vaccinating senior people.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by product
    • 1.4.2. Market size breakdown, by test type
    • 1.4.3. Market size breakdown, by end user
    • 1.4.4. Market size breakdown, by region
    • 1.4.5. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Product (2017-2030)
  • 6.3. Market Revenue, by Test Type (2017-2030)
    • 6.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 6.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 6.4. Market Revenue, by End User (2017-2030)
  • 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Product (2017-2030)
  • 7.3. Market Revenue, by Test Type (2017-2030)
    • 7.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 7.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 7.4. Market Revenue, by End User (2017-2030)
  • 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Product (2017-2030)
  • 8.3. Market Revenue, by Test Type (2017-2030)
    • 8.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 8.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 8.4. Market Revenue, by End User (2017-2030)
  • 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Product (2017-2030)
  • 9.3. Market Revenue, by Test Type (2017-2030)
    • 9.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 9.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 9.4. Market Revenue, by End User (2017-2030)
  • 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Product (2017-2030)
  • 10.3. Market Revenue, by Test Type (2017-2030)
    • 10.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 10.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 10.4. Market Revenue, by End User (2017-2030)
  • 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Product (2017-2030)
  • 11.3. Market Revenue, by Test Type (2017-2030)
    • 11.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 11.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 11.4. Market Revenue, by End User (2017-2030)
  • 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Product (2017-2030)
  • 12.3. Market Revenue, by Test Type (2017-2030)
    • 12.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 12.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Product (2017-2030)
  • 13.3. Market Revenue, by Test Type (2017-2030)
    • 13.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 13.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Product (2017-2030)
  • 14.3. Market Revenue, by Test Type (2017-2030)
    • 14.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 14.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Product (2017-2030)
  • 15.3. Market Revenue, by Test Type (2017-2030)
    • 15.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 15.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Product (2017-2030)
  • 16.3. Market Revenue, by Test Type (2017-2030)
    • 16.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 16.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Product (2017-2030)
  • 17.3. Market Revenue, by Test Type (2017-2030)
    • 17.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 17.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Product (2017-2030)
  • 18.3. Market Revenue, by Test Type (2017-2030)
    • 18.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 18.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Product (2017-2030)
  • 19.3. Market Revenue, by Test Type (2017-2030)
    • 19.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 19.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Product (2017-2030)
  • 20.3. Market Revenue, by Test Type (2017-2030)
    • 20.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 20.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Product (2017-2030)
  • 21.3. Market Revenue, by Test Type (2017-2030)
    • 21.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 21.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Product (2017-2030)
  • 22.3. Market Revenue, by Test Type (2017-2030)
    • 22.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 22.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Product (2017-2030)
  • 23.3. Market Revenue, by Test Type (2017-2030)
    • 23.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 23.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Product (2017-2030)
  • 24.3. Market Revenue, by Test Type (2017-2030)
    • 24.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 24.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Product (2017-2030)
  • 25.3. Market Revenue, by Test Type (2017-2030)
    • 25.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 25.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Product (2017-2030)
  • 26.3. Market Revenue, by Test Type (2017-2030)
    • 26.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 26.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Product (2017-2030)
  • 27.3. Market Revenue, by Test Type (2017-2030)
    • 27.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 27.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Product (2017-2030)
  • 28.3. Market Revenue, by Test Type (2017-2030)
    • 28.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
    • 28.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
  • 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. 3M Company
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. Abbott Laboratories Inc.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Becton, Dickinson and Company
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Meridian Bioscience Inc.
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. QuidelOrtho Corporation
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. F. Hoffmann-La Roche Ltd.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. SA Scientific Ltd.
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. Sekisui Diagnostics LLC
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. Thermo Fisher Scientific Inc.
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary
  • 30.10. Hologic Inc.
    • 30.10.1. Business overview
    • 30.10.2. Product and service offerings
    • 30.10.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports